The Department of Health and Human Services and Drug Enforcement Administration Dec. 30 released a temporary rule extending for the fourth time waiver flexibilities for prescribing controlled substances via telemedicine. The waivers allow for the prescribing of schedule II-V controlled substances (including schedule III-V medications approved by the Food and Drug Administration for treatment of opioid use disorder) via audio-video telemedicine encounter without a prior in-person medical evaluation through Dec. 31, 2026. These flexibilities apply to all practitioner-patient relationships, not just those established during the COVID-19 public health emergency. The waivers were due to expire on Dec. 31, 2025; by extending them for another year, the agencies have additional time to develop and implement a permanent special registration process for prescribing of controlled substances.

Related News Articles

Headline
Wendy Kim, DNP, R.N., vice president and chief nursing officer of Henry Ford Health in Michigan, shares how the system’s virtual nursing program is reducing…
Headline
The Centers for Medicare & Medicaid Services will retroactively pay claims for telehealth services provided during the government shutdown through Jan. 30…
Headline
The 43-day government shutdown ended last night when President Trump signed a funding bill into law, hours after the House passed the measure by a 222-209 vote…
Chairperson's File
Public
This week brings the fourth week of the federal government shutdown as Congress has yet to pass legislation to fund the government. This shutdown is a bit…
Headline
Members of the AHA Board of Trustees Oct.14 participated in a panel on the future of rural health care during the Sanford Rural Health Summit in Sioux Falls, S…
Headline
The AHA detailed its key health care priorities for the remainder of the year in comments to House and Senate majority and minority leaders Sept. 15. The AHA…